Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tolerability of Enteral N-Acetylcysteine in Infants with Biliary Atresia
NCT06260566Phase 1Not yet recruiting
- Start
- Oct 2026
- Primary completion
- Oct 2030
- Modality
- Small Molecules
01
Overview
Phase 1, open-label, single-arm trial of acetylcysteine in biliary atresia. Primary endpoint: Tolerability (No emesis). Planned start Oct 2026; status: not yet recruiting.
02
Drugs
acetylcysteine
03
Conditions
biliary atresia
Beyond the preview
Go deeper on NCT06260566.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06260566.